What Is the Outcome in Patients With Acute Leukaemia Who Survive Severe Acute Graft-Versus-Host Disease? Publisher Pubmed



Ringden O¹ ; Labopin M² ; Sadeghi B¹ ; Mailhol A² ; Beelen D³ ; Floisand Y⁴ ; Ghavamzadeh A⁵ ; Finke J⁶ ; Ehninger G⁷ ; Volin L⁸ ; Socie G⁹ ; Kroger N¹⁰ ; Stuhler G¹¹ ; Ganser A¹² Show All Authors Show Affiliations
Source: Journal of Internal Medicine Published:2018

Abstract

Background: Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic haematopoietic stem cell transplantation (HSCT). With new promising therapies, survival may improve for severe aGVHD. Objectives: We wanted to analyze the long-term outcome in patients who survive severe aGVHD. Methods: This study was a landmark analysis of 23 567 patients with acute Leukaemia who survived for more than 6 months after HSCT, 2002–2014. Patients alive after severe aGVHD (n = 1738) were compared to controls. Results: Patients with severe aGVHD had higher non-relapse mortality (NRM) and higher rate of extensive chronic GVHD (cGVHD) than the controls (P < 10−5). The probability of relapse was significantly lower in the severe aGVHD group, but Leukaemia-free survival (LFS) and overall survival were significantly lower than for the controls (P < 10−5). Five-year LFS in patients with severe aGVHD was 49%, as opposed to 61% in controls with no or mild GVHD and 59% in patients with moderate GVHD. Conclusions: HSCT patients who survive severe aGVHD have higher risk of developing extensive cGVHD, a higher NRM, a lower relapse probability, and lower LFS than other HSCT patients. This study is a platform for outcome analysis in patients treated with novel therapies for acute GVHD. © 2017 The Association for the Publication of the Journal of Internal Medicine